A Phase 1 interventional study of Ixekizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-08.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare two different formulations of ixekizumab. One formulation (Reference) is approved by the Food and Drug Administration (FDA) and one formulation (Test) is not approved. This study will compare how much of each formulation gets into the blood stream. Information about any side effects that may occur will also be collected. The study will last up to about four months for each participant.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approved formulation of 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
Drug: Ixekizumab
Test formulation of 80 mg ixekizumab administered as a SC injection via AI.
Drug: Ixekizumab
Administered SC.
Also known as: LY2439821
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab
PK: Cmax of ixekizumab was evaluated
Time frame: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab
Area under the plasma concentration versus time curve from time zero to the last measured concentration value (AUC\[0-tlast\]). AUC 0-tlast is equal to AUC (0-85) days where the last time point was 85 Days ± 3 Days.
Time frame: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab
Area under the plasma concentration versus time curve from zero to infinity (AUC\[0-∞\]) of a single dose of Ixekizumab.
Time frame: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
| Milestone | 80 Milligram (mg) Ixekizumab (Reference) | 80 mg Ixekizumab (Test) |
|---|---|---|
| Started | 126 | 119 |
| Received at least one dose of study drug | 126 | 119 |
| Completed | 122 | 115 |
| Not completed | 4 | 4 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
PK: Cmax of ixekizumab was evaluated
| micrograms per milliliter (ug/mL) | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab | 9.66 ± 33 | 9.97 ± 35 |
Area under the plasma concentration versus time curve from time zero to the last measured concentration value (AUC\[0-tlast\]). AUC 0-tlast is equal to AUC (0-85) days where the last time point was 85 Days ± 3 Days.
| microgram*day/milliliter (ug*day/mL) | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab | 207 ± 31 | 219 ± 28 |
Area under the plasma concentration versus time curve from zero to infinity (AUC\[0-∞\]) of a single dose of Ixekizumab.
| ug*day/mL | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab | 213 ± 33 | 227 ± 30 |
Collected over Up to 85 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 80 mg Ixekizumab (Reference) | 0/126 (0%) | 0/126 (0%) | 36/126 (28.6%) |
| 80 mg Ixekizumab (Test) | 0/119 (0%) | 0/119 (0%) | 14/119 (11.8%) |
| Event | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) |
|---|---|---|
| Injection site reactionGeneral disorders | 30/126 | 11/119 |
| HeadacheNervous system disorders | 9/126 | 3/119 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) | Total |
|---|---|---|---|
| Mean | 42.9 ± 12.8 | 46.8 ± 13.5 | 44.8 ± 13.2 |
| Sex: Female, Male(Participants) | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) | Total |
|---|---|---|---|
| Female | 67 | 60 | 127 |
| Male | 59 | 59 | 118 |
| Ethnicity (NIH/OMB)(Participants) | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) | Total |
|---|---|---|---|
| Hispanic or Latino | 58 | 46 | 104 |
| Not Hispanic or Latino | 68 | 73 | 141 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 32 | 19 | 51 |
| White | 93 | 98 | 191 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 80 mg Ixekizumab (Reference) | 80 mg Ixekizumab (Test) | Total |
|---|---|---|---|
| United States | 126 | 119 | 245 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Feb 2021, 12 months.
Results were first posted in Apr 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab